RDY
Income statement / Annual
Last year (2024), Dr. Reddy's Laboratories Limited's total revenue was $279.16 B,
an increase of 13.54% from the previous year.
In 2024, Dr. Reddy's Laboratories Limited's net income was $55.68 B.
See Dr. Reddy's Laboratories Limited,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
03/31/2024 |
03/31/2023 |
03/31/2022 |
03/31/2021 |
03/31/2020 |
03/31/2019 |
03/31/2018 |
03/31/2017 |
03/31/2016 |
03/31/2015 |
| Operating Revenue |
$279.16 B |
$245.88 B |
$214.39 B |
$189.72 B |
$174.60 B |
$153.85 B |
$142.03 B |
$140.81 B |
$154.71 B |
$148.19 B |
| Cost of Revenue |
$115.56 B
|
$42.91 B
|
$100.55 B
|
$86.65 B
|
$80.59 B
|
$70.42 B
|
$65.72 B
|
$62.45 B
|
$62.43 B
|
$62.79 B
|
| Gross Profit |
$163.61 B
|
$202.97 B
|
$113.84 B
|
$103.08 B
|
$94.01 B
|
$83.43 B
|
$76.30 B
|
$78.36 B
|
$92.28 B
|
$85.40 B
|
| Gross Profit Ratio |
0.59
|
0.83
|
0.53
|
0.54
|
0.54
|
0.54
|
0.54
|
0.56
|
0.6
|
0.58
|
| Research and Development Expenses |
$22.87 B
|
$19.38 B
|
$17.48 B
|
$16.54 B
|
$15.41 B
|
$15.61 B
|
$18.27 B
|
$19.55 B
|
$17.83 B
|
$17.45 B
|
| General & Administrative Expenses |
$0.00
|
$46.47 B
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$59.47 B
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$77.20 B
|
$105.93 B
|
$62.08 B
|
$54.56 B
|
$50.13 B
|
$48.89 B
|
$46.91 B
|
$46.37 B
|
$45.70 B
|
$42.59 B
|
| Other Expenses |
-$4.20 B
|
-$7.70 B
|
-$2.76 B
|
-$982.00 M
|
-$4.29 B
|
-$691.00 M
|
-$843.00 M
|
-$1.15 B
|
-$986.00 M
|
-$1.06 B
|
| Operating Expenses |
$95.88 B
|
$117.62 B
|
$76.80 B
|
$70.12 B
|
$61.25 B
|
$62.54 B
|
$64.39 B
|
$64.86 B
|
$62.66 B
|
$59.12 B
|
| Cost And Expenses |
$211.44 B
|
$160.52 B
|
$177.35 B
|
$156.76 B
|
$141.84 B
|
$132.96 B
|
$130.11 B
|
$127.31 B
|
$125.09 B
|
$121.90 B
|
| Interest Income |
$2.28 B
|
$1.18 B
|
$3.08 B
|
$2.62 B
|
$888.00 M
|
$2.28 B
|
$540.00 M
|
$558.00 M
|
$1.40 B
|
$1.06 B
|
| Interest Expense |
$1.71 B
|
$1.43 B
|
$958.00 M
|
$970.00 M
|
$983.00 M
|
$1.16 B
|
$788.00 M
|
$634.00 M
|
$826.00 M
|
$1.09 B
|
| Depreciation & Amortization |
$14.84 B
|
$12.64 B
|
$11.82 B
|
$12.80 B
|
$12.47 B
|
$12.19 B
|
$11.71 B
|
$11.28 B
|
$10.25 B
|
$8.10 B
|
| EBITDA |
$88.42 B |
$74.43 B |
$47.74 B |
$45.71 B |
$41.79 B |
$31.87 B |
$23.74 B |
$24.55 B |
$40.18 B |
$35.16 B |
| EBITDA Ratio |
0.32
|
0.3
|
0.22
|
0.24
|
0.24
|
0.21
|
0.17
|
0.17
|
0.26
|
0.24
|
| Operating Income Ratio |
0.24
|
0.39
|
0.19
|
0.19
|
0.21
|
0.14
|
0.08
|
0.1
|
0.19
|
0.18
|
| Total Other Income/Expenses Net |
$4.14 B
|
$3.34 B
|
$2.82 B
|
$4.04 B
|
$2.04 B
|
$1.56 B
|
$2.42 B
|
$1.16 B
|
-$2.48 B
|
$1.88 B
|
| Income Before Tax |
$71.87 B
|
$60.49 B
|
$32.30 B
|
$28.32 B
|
$18.03 B
|
$22.44 B
|
$14.34 B
|
$14.65 B
|
$27.14 B
|
$28.16 B
|
| Income Before Tax Ratio |
0.26
|
0.25
|
0.15
|
0.15
|
0.1
|
0.15
|
0.1
|
0.1
|
0.18
|
0.19
|
| Income Tax Expense |
$16.19 B
|
$15.41 B
|
$8.73 B
|
$9.18 B
|
-$1.47 B
|
$3.65 B
|
$4.54 B
|
$2.61 B
|
$7.13 B
|
$5.98 B
|
| Net Income |
$55.68 B
|
$45.07 B
|
$23.57 B
|
$17.24 B
|
$19.50 B
|
$18.80 B
|
$9.81 B
|
$12.04 B
|
$20.01 B
|
$22.18 B
|
| Net Income Ratio |
0.2
|
0.18
|
0.11
|
0.09
|
0.11
|
0.12
|
0.07
|
0.09
|
0.13
|
0.15
|
| EPS |
66.8 |
54.29 |
28.42 |
20.79 |
23.53 |
22.66 |
11.83 |
14.45 |
23.47 |
26.04 |
| EPS Diluted |
66.8 |
54.17 |
28.34 |
20.73 |
23.48 |
22.62 |
11.8 |
14.42 |
23.4 |
25.95 |
| Weighted Average Shares Out |
$833.54 M
|
$830.17 M
|
$829.41 M
|
$829.22 M
|
$828.79 M
|
$829.58 M
|
$829.23 M
|
$833.24 M
|
$852.74 M
|
$851.57 M
|
| Weighted Average Shares Out Diluted |
$833.54 M
|
$831.91 M
|
$831.69 M
|
$831.58 M
|
$830.41 M
|
$830.98 M
|
$830.93 M
|
$834.99 M
|
$855.36 M
|
$854.67 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
